Newsletter summary
Ganli Pharmaceutical Co., Ltd.: a number of products intend to win the bid for the national drug collection (insulin special continuation) Securities Times e company newsCrouchingtigerhiddendragon1Ganli Pharmaceutical (603087) announced on the evening of April 23rd that the company participated in the national centralized drug procurement organized by the State-organized centralized Drug Purchasing and the use of Joint Purchasing Office.Crouchingtigerhiddendragon1...
Text of news flash
Ganli Pharmaceutical Co., Ltd.: a number of products intend to win the bid for national drug collection (insulin special continuation) Securities Times e, Ganli Pharmaceutical Co., Ltd. (603087) announced on the evening of April 23rd, the company participated in the bidding work of national centralized drug procurement (insulin special continuation) organized by the state-organized centralized drug procurement and use joint procurement office. According to the public document of the proposed successful selection results, the protamine human insulin mixed injection (30R), Lai Pu insulin injection, Mendong insulin injection, glargine insulin injection, protamine zinc recombinant Lai Pu insulin mixed injection (25R) and Mendong insulin 30 injection and other varieties of protamine human insulin mixed injection (30R), Lai Pu insulin injection, Mendong insulin 30 injection and other varieties of protamine human insulin mixed injection (30R), Lai Pu insulin injection, Mendong insulin 30 injection and so on, were qualified to be selected in the continuous purchase of insulin, and all the participating groups were selected A varieties. The total sales of the six products and related products that the company intends to win the bid in 2022 are 1.369 billion yuan, accounting for 79.96%, and the total sales in the first three quarters of 2023 are 1.582 billion yuan, accounting for 82.99%.